Adverse drug reactions of intravesical bacillus Calmette-Guérin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder

International Journal of Urology

Volumn 12, Issue 2, 2005, Pages 145-151

  Koga, Hirofumi ^a   Kuroda, Masao ^b   Kudo, Seiji ^c   Yamaguchi, Akito ^d   Usami, Michiyuki ^e   Suzuki, Tadashi ^c   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Nissei Hospital   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d HARASANSHIN HOSPITAL   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Adverse drug reaction; Bacillus Calmette Gu rin; Bladder cancer; Carcinoma in situ; Intravesical instillation

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BCG VACCINE;

ADULT; ADVERSE DRUG REACTION; AGED; ANOREXIA; ARTICLE; BLADDER CANCER; BLADDER DISEASE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOMA IN SITU; CARDIOVASCULAR DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG INSTILLATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; EYE DISEASE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION; HEMATURIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MALE GENITAL SYSTEM DISEASE; MICTURITION DISORDER; MULTIVARIATE ANALYSIS; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PYURIA; RESPIRATORY TRACT DISEASE; RISK FACTOR; SKIN MANIFESTATION; SUPERFICIAL CANCER; VISUAL DISORDER;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 16244385030     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01000.x     Document Type: Article

References (16)

1. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 1991; 325: 1205-9.
2. Lamm DL, Van der Meijden APM, Akaza H et al. Intravesical chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Int. J. Urol. 1995; 2 (Suppl. 2): 23-35.
3. Lamm DL. Efficacy and safety of Bacillus Calmette-Guérin immunotherapy in superficial bladder cancer. Clin. Infect. Dis. 2000; 31: s86-90.
4. Van der Meijden APM, Brausi M, Zanbon V et al. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette- Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinaty Group randomized phase III trial. J Urol. 2001; 166: 476-81.
5. DeHaven JI, Traynellis C, Riggs DR, Ting E, Lamm DL. Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity. J. Urol. 1992; 147: 738-42.
6. Lamm DL, Van der Meijden APM, Morales A et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol. 1992; 147: 596-600.
7. Japanese Urological Association and Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 2nd edn. Kanehara Shuppann, Tokyo, 1993.
8. Van der Meijden APM. Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur. Urol. 1995; 27 (Suppl. 1): 23-8.
9. Akaza H. Adverse effects of intravesical Bacillus Calmette-Guérin instillation for superficial bladder cancer. Ann. Soc. BCG BRM Immunother. 1999; 23: 59-65. (In Japanese.)
10. Bassi P. Methodology in superficial bladder cancer clinical trials: objective evaluation of treatment: the need of standardization. In: Pagano F, Fair WR (eds). Superficial Bladder Cancer. Isis Medical Media, Oxford, 1997; 82-9.
11. Saint F, Irani J, Patard JJ et al. Tolerability of bacillus Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 883-8.
12. Orihuela E, Herr HW, Pinsky CM, Whitmore WF Jr. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60: 326-33.
13. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillation: recommendations for side-effects management. Eur. Urol. 2000; 37 (Suppl. 1): 33-6.
14. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 1991; 146: 32-5.
15. Lebret T, Bohin D, Kassardjian Z et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations. J. Urol. 2000; 163: 63-7.
16. Irie A, Uchida T, Yamashita H et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence. Int, J. Urol. 2003; 10: 183-9.